Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with relapsed or refractory, advanced non-small cell lung cancer (LUME-Lung 2): A randomized, double-blind, phase III trial.
Hanna NH, Kaiser R, Sullivan RN, Aren OR, Ahn MJ, Tiangco B, Voccia I, Pawel JV, Kovcin V, Agulnik J, Gaschler-Markefski B, Barrueco J, Sikken P, Schloss C, Kim JH; LUME-Lung 2 Study group. Hanna NH, et al. Among authors: sullivan rn. Lung Cancer. 2016 Dec;102:65-73. doi: 10.1016/j.lungcan.2016.10.011. Epub 2016 Oct 27. Lung Cancer. 2016. PMID: 27987591 Clinical Trial.
Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J. McKeage MJ, et al. Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5. Lung Cancer. 2009. PMID: 19409645 Clinical Trial.
Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
Gandara DR, von Pawel J, Mazieres J, Sullivan R, Helland Å, Han JY, Ponce Aix S, Rittmeyer A, Barlesi F, Kubo T, Park K, Goldschmidt J, Gandhi M, Yun C, Yu W, Matheny C, He P, Sandler A, Ballinger M, Fehrenbacher L. Gandara DR, et al. J Thorac Oncol. 2018 Dec;13(12):1906-1918. doi: 10.1016/j.jtho.2018.08.2027. Epub 2018 Sep 11. J Thorac Oncol. 2018. PMID: 30217492 Free article. Clinical Trial.
Osimertinib in NSCLC: Real-World Data From New Zealand.
So YJ, Fraser A, Rivalland G, McKeage M, Sullivan R, Cameron L. So YJ, et al. JTO Clin Res Rep. 2020 Mar 10;1(2):100022. doi: 10.1016/j.jtocrr.2020.100022. eCollection 2020 Jun. JTO Clin Res Rep. 2020. PMID: 34589929 Free PMC article.
Mind the Graph: Foregone Health Gains in Lung Cancer.
Cameron L, Sullivan R, Luey B, Solomon B. Cameron L, et al. Semin Oncol. 2018 Oct;45(5-6):316-317. doi: 10.1053/j.seminoncol.2017.11.004. Epub 2017 Dec 6. Semin Oncol. 2018. PMID: 30262394 No abstract available.
A workforce survey of New Zealand medical oncologists.
Bidwell S, Simpson A, Sullivan R, Robinson B, Thomas W, Jackson C, Forgeson G, Jameson M, Clarke T. Bidwell S, et al. N Z Med J. 2013 Mar 15;126(1371):45-53. N Z Med J. 2013. PMID: 23793120